COMMUNIQUÉS West-GlobeNewswire

HealthEquity Announces Record Year-End HSA Sales Outlook, Presentation at J.P. Morgan Healthcare Conference

13/01/2025 - 15:01

DRAPER, Utah, Jan. 13, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation’s largest health savings account (“HSA") custodian, today announced estimates of HSAs, HSA [...]

Avance Clinical Leads as the CRO of Choice for Early Phase Clinical Trials in Australia – Announced at Biotech Showcase 2025

13/01/2025 - 15:07

WAKE FOREST, N.C. and ADELAIDE, Australia, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Avance Clinical , a leading full-service global Contract Research Organization (CRO) known for delivering high-quality, agile clinical [...]

Positron Corporation Engages Skyline Corporate Communications Group, LLC to Enhance Investor Relations and Financial Community Outreach

13/01/2025 - 15:15

Niagara Falls, NY, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Positron Corporation ("Positron" or the "Company") (OTC: POSC), a leading molecular imaging medical device company offering PET and PET-CT (Positron Emission [...]

NAYA Biosciences Announces Pricing of $9.5 Million Public Offering

13/01/2025 - 15:15

SARASOTA, Fla. and MIAMI, Jan. 13, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune [...]

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

13/01/2025 - 15:16

Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated [...]

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

13/01/2025 - 15:27

This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and procurement of Ebanga™, with a maximum value of $704 million Program progress and performance triggers $16.7 million [...]

Baylor Genetics to Integrate with Epic Aura to Enhance Efficiency and Deliver Genetic Testing Results to Hospitals and Health Systems

13/01/2025 - 16:00

The company will be the first to integrate whole genome sequencing (WGS) into Epic's Aura platform, further advancing access to genetic insights for patients and providers in the neonatal and pediatric intensive care [...]

ProMIS Neurosciences Issues Letter to Shareholders

13/01/2025 - 16:30

CAMBRIDGE, Massachusetts, Jan. 13, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (ProMIS), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics [...]

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

13/01/2025 - 17:00

Company announcement – No. 1 / 2025 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, January [...]

BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones

13/01/2025 - 17:00

- Remarkable early Attruby demand: 430 scripts written by 248 unique HCPs since FDA approval with broad uptake across academic centers and community centers in all patient types - Fully enrolled three major market Phase [...]

Press release: Transparency Notification from Shareholders

13/01/2025 - 17:30

Transparency Notification from Shareholders Ghent, Belgium – 13 January 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of fluid overload in [...]

OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief Development Officer

13/01/2025 - 18:00

OSE Immunotherapeutics annonce la nomination du Dr. Sonya Montgomery au poste de Chief Development Officer Nantes, France, le 13 janvier 2025, 18 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) [...]

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

13/01/2025 - 18:00

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer NANTES, France, January 13, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today announced the [...]

Correction: GUERBET : Calendrier financier de l'exercice 2025

13/01/2025 - 18:00

Calendrier financier de l’exercice 2025 Villepinte, le 13 janvier 2025 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, publie son calendrier financier [...]

Correction: GUERBET : Financial agenda for 2025

13/01/2025 - 18:00

Financial agenda for 2025 Villepinte, 13 janvier 2025 : Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is announcing its financial agenda for 2025. Publications [...]

Merus et Biohaven annoncent une collaboration pour co-développer trois nouveaux programmes de CAM bispécifiques

13/01/2025 - 18:24

NEW HAVEN, Connecticut, et UTRECHT, Pays-Bas et CAMBRIDGE, Massachusetts, 13 janv. 2025 (GLOBE NEWSWIRE) -- Biohaven Ltd. (NYSE : BHVN) et Merus N.V. (Nasdaq : MRUS) ont annoncé ce jour une collaboration de recherche et [...]

Micron Biomedical Wins $2 Million BARDA Competition for Its Collaboration with Zipcode Bio to Develop mRNA-Based Broad Protecting Flu Vaccine Without Needles

13/01/2025 - 20:00

U.S. Department of Health and Human Services (HHS) office, BARDA, awards Micron $2 million to continue its work on broadly-protecting avian and seasonal flu vaccines SAN FRANCISCO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- [...]

OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2024 and Issues 2025 Financial Guidance

13/01/2025 - 22:00

Achieves all-time high full year 2024 Revenue of $205 million representing growth of 38% Year-Over-Year Initiates guidance for record adjusted EBITDA in 2025 WARSAW, Ind., Jan. 13, 2025 (GLOBE NEWSWIRE) -- [...]

Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF

13/01/2025 - 22:05

Informations Réglementées Châtillon, France, le 13 janvier 2025 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq : DBVT), [...]